Details
Stereochemistry | ACHIRAL |
Molecular Formula | C13H22N4O3S |
Molecular Weight | 314.404 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CNC(NCCSCC1=CC=C(CN(C)C)O1)=C[N+]([O-])=O
InChI
InChIKey=VMXUWOKSQNHOCA-LCYFTJDESA-N
InChI=1S/C13H22N4O3S/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3/h4-5,9,14-15H,6-8,10H2,1-3H3/b13-9-
Molecular Formula | C13H22N4O3S |
Molecular Weight | 314.404 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/2667937,6309467
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2667937,6309467
Ranitidine, a histamine H2-receptor antagonist, is now well established as a potent inhibitor of gastric acid secretion effective in the treatment and prophylaxis of gastrointestinal lesions aggravated by gastric acid secretion.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1444693
Curator's Comment: Ranitidine, when given in conventional doses, can cause adverse central nervous system reactions (CNS-ADRs), particularly in older patients who have substantial renal function impairment. These CNS-ADRs occur as a consequence of altered ranitidine disposition. Ranitidine doses should be reduced when renal function impairment is present, and patients should be carefully observed for CNS-ADRs.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P25102 Gene ID: 25461.0 Gene Symbol: Hrh2 Target Organism: Rattus norvegicus (Rat) Sources: http://www.pnas.org/content/93/13/6802.full.pdf |
0.14 µM [Ki] | ||
Target ID: P47747 Gene ID: NA Gene Symbol: HRH2 Target Organism: Cavia porcellus (Guinea pig) Sources: https://www.ncbi.nlm.nih.gov/pubmed/9205741 |
0.19 µM [Ki] | ||
Target ID: P25021 Gene ID: 3274.0 Gene Symbol: HRH2 Target Organism: Homo sapiens (Human) Sources: http://ca.gsk.com/media/592906/zantac.pdf |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ZANTAC 150 Approved UseZANTAC® (ranitidine hydrochloride) Tablets and Injection are indicated for the treatment of duodenal ulcer, benign gastric ulcer, reflux esophagitis, post-operative peptic ulcer, Zollinger-Ellison Syndrome, and other conditions where reduction of gastric secretion
and acid output is desirable. These include the following:
• the treatment of nonsteroidal anti-inflammatory drug (NSAID)- induced lesions, both ulcers and erosions, and their gastrointestinal (GI) symptoms and the prevention of their recurrence;
• the prophylaxis of GI hemorrhage from stress ulceration in seriously ill patients;
• the prophylaxis of recurrent hemorrhage from bleeding ulcers;
• the prevention of Acid Aspiration Syndrome from general anaesthesia in patients considered to be at risk for this, including obstetrical patients in labour, and obese patients.
In addition, ZANTAC® is indicated for the prophylaxis and maintenance treatment of duodenal or benign gastric ulcer in patients with a history of recurrent ulceration. Launch Date4.23964803E11 |
|||
Primary | ZANTAC 150 Approved UseZANTAC® (ranitidine hydrochloride) Tablets and Injection are indicated for the treatment of duodenal ulcer, benign gastric ulcer, reflux esophagitis, post-operative peptic ulcer, Zollinger-Ellison Syndrome, and other conditions where reduction of gastric secretion
and acid output is desirable. These include the following:
• the treatment of nonsteroidal anti-inflammatory drug (NSAID)- induced lesions, both ulcers and erosions, and their gastrointestinal (GI) symptoms and the prevention of their recurrence;
• the prophylaxis of GI hemorrhage from stress ulceration in seriously ill patients;
• the prophylaxis of recurrent hemorrhage from bleeding ulcers;
• the prevention of Acid Aspiration Syndrome from general anaesthesia in patients considered to be at risk for this, including obstetrical patients in labour, and obese patients.
In addition, ZANTAC® is indicated for the prophylaxis and maintenance treatment of duodenal or benign gastric ulcer in patients with a history of recurrent ulceration. Launch Date4.23964803E11 |
|||
Primary | ZANTAC 150 Approved UseZANTAC® (ranitidine hydrochloride) Tablets and Injection are indicated for the treatment of duodenal ulcer, benign gastric ulcer, reflux esophagitis, post-operative peptic ulcer, Zollinger-Ellison Syndrome, and other conditions where reduction of gastric secretion
and acid output is desirable. These include the following:
• the treatment of nonsteroidal anti-inflammatory drug (NSAID)- induced lesions, both ulcers and erosions, and their gastrointestinal (GI) symptoms and the prevention of their recurrence;
• the prophylaxis of GI hemorrhage from stress ulceration in seriously ill patients;
• the prophylaxis of recurrent hemorrhage from bleeding ulcers;
• the prevention of Acid Aspiration Syndrome from general anaesthesia in patients considered to be at risk for this, including obstetrical patients in labour, and obese patients.
In addition, ZANTAC® is indicated for the prophylaxis and maintenance treatment of duodenal or benign gastric ulcer in patients with a history of recurrent ulceration. Launch Date4.23964803E11 |
|||
Primary | ZANTAC 150 Approved UseZANTAC® (ranitidine hydrochloride) Tablets and Injection are indicated for the treatment of duodenal ulcer, benign gastric ulcer, reflux esophagitis, post-operative peptic ulcer, Zollinger-Ellison Syndrome, and other conditions where reduction of gastric secretion
and acid output is desirable. These include the following:
• the treatment of nonsteroidal anti-inflammatory drug (NSAID)- induced lesions, both ulcers and erosions, and their gastrointestinal (GI) symptoms and the prevention of their recurrence;
• the prophylaxis of GI hemorrhage from stress ulceration in seriously ill patients;
• the prophylaxis of recurrent hemorrhage from bleeding ulcers;
• the prevention of Acid Aspiration Syndrome from general anaesthesia in patients considered to be at risk for this, including obstetrical patients in labour, and obese patients.
In addition, ZANTAC® is indicated for the prophylaxis and maintenance treatment of duodenal or benign gastric ulcer in patients with a history of recurrent ulceration. Launch Date4.23964803E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
440 ng/mL |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
RANITIDINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
948.6 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6094785/ |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
RANITIDINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.69 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6094785/ |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
RANITIDINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
2.5 h |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
RANITIDINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
85% |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
RANITIDINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
100 mg single, oral Highest studied dose |
healthy, adult n = 136 Health Status: healthy Age Group: adult Sex: M+F Population Size: 136 Sources: |
|
1500 mg single, oral Overdose Dose: 1500 mg Route: oral Route: single Dose: 1500 mg Sources: |
unknown, children n = 517 Health Status: unknown Age Group: children Sex: unknown Population Size: 517 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
no | ||||
no | no (co-administration study) Comment: Ranitidine has no effect on midazolam exposure Sources: https://pubmed.ncbi.nlm.nih.gov/10223772/ |
|||
weak [IC50 290 uM] | ||||
weak | ||||
yes [IC50 114 uM] | ||||
yes [IC50 18.9 uM] | ||||
yes [IC50 28 uM] | ||||
yes [Ki 25 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major | ||||
minor | ||||
minor | ||||
no | ||||
no | ||||
no | ||||
no | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Comparison of ranitidine and high-dose antacid in the treatment of prepyloric or duodenal ulcer. A double-blind controlled trial. | 1985 Jan |
|
Bradycardia and neurologic disorders associated with ranitidine in a child. | 1985 May |
|
Mental confusion as a side effect of ranitidine. | 1986 Feb |
|
Depression associated with ranitidine. | 1986 Jul |
|
Myofascial headache. Exacerbation of symptoms due to diflunisal and ranitidine therapy. A case report. | 1987 Aug |
|
Histamine and hepatic glutathione in the mouse. | 1987 May 25 |
|
Mania associated with intravenous ranitidine therapy. | 1987 Nov |
|
Fatal renal and hepatic toxicity after treatment with diltiazem. | 1987 Nov 14 |
|
Famotidine-associated mental confusion in elderly patients. | 1988 Dec |
|
Reversible chorea due to ranitidine and cimetidine. | 1988 Jul 16 |
|
Ranitidine and bradycardia. | 1988 Mar |
|
Cardiac arrest associated with ranitidine. | 1989 Aug 19 |
|
Famotidine and ranitidine, but not cimetidine, cause severe, disabling headache. | 1989 Feb |
|
Ranitidine-induced chest pain. | 1989 Mar |
|
Histamine release in the isolated vascularly perfused stomach of the rat: regulation by autoreceptors. | 1989 Mar |
|
Effect of ranitidine on acetaminophen-induced hepatotoxicity in dogs. | 1990 Mar |
|
Effects of histamine H2-receptor blockade on the cardiovascular reflex response to lower-body negative pressure in man. | 1990 May |
|
Seizures during concomitant treatment with theophylline and ranitidine: a case report. | 1990 Oct-Dec |
|
Ranitidine-associated delirium. | 1990 Winter |
|
Ranitidine and depression. | 1991 Sep |
|
Ranitidine pharmacokinetics and adverse central nervous system reactions. | 1992 Nov |
|
Effects of three H2-receptor antagonists (cimetidine, famotidine, ranitidine) on serum gastrin level. | 2002 |
|
Effects of H(2)-receptor antagonists on dapsone-induced methaemoglobinaemia in rats. | 2002 Apr |
|
Are proton pump inhibitors the first choice for acute treatment of gastric ulcers? A meta analysis of randomized clinical trials. | 2002 Jul 15 |
|
Histamine H(2) -like receptors in chick cerebral cortex: effects on cyclic AMP synthesis and characterization by [(3) H]tiotidine binding. | 2002 Jun |
|
Drug points: Severe myalgia from an interaction between treatments with pantoprazole and methotrexate. | 2002 Jun 22 |
|
Effects of histamine H(2)-receptor antagonists on human plasma levels of calcitonin gene-related peptide, substance P and vasoactive intestinal peptide. | 2002 Nov |
|
Extremely early onset of ranitidine action on human histamine H2 receptors expressed in HEK293 cells. | 2003 |
|
Radioprotective properties of histamine H2 receptor antagonists: present and future prospects. | 2003 Jun |
|
Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. | 2004 Nov |
|
Carrier-mediated uptake of H2-receptor antagonists by the rat choroid plexus: involvement of rat organic anion transporter 3. | 2004 Sep |
|
Lethal cardiomyopathy in epidermolysis bullosa associated with amitriptyline. | 2005 Aug |
|
Role of histamine in airway remodeling of asthmatic guinea pig. | 2005 Dec 25 |
|
Weak inhibitors protect cholinesterases from strong inhibitors (paraoxon): in vitro effect of ranitidine. | 2005 Jan-Feb |
|
Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
|
Intracerebroventricular effects of histaminergic agents on morphine-induced anxiolysis in the elevated plus-maze in rats. | 2005 Nov |
|
Excitatory effect of histamine on neuronal activity of rat globus pallidus by activation of H2 receptors in vitro. | 2005 Nov |
|
A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. | 2005 Oct |
|
Antisecretory and antiulcer activity of Asparagus racemosus Willd. against indomethacin plus phyloric ligation-induced gastric ulcer in rats. | 2006 |
|
Cimetidine induces interleukin-18 production through H2-agonist activity in monocytes. | 2006 Aug |
|
Attenuation of indomethacin- and HCl/ethanol-induced oxidative gastric mucosa damage in rats by kolaviron, a natural biflavonoid of Garcinia kola seed. | 2006 Jan |
|
Coagulation-dependent gene expression and liver injury in rats given lipopolysaccharide with ranitidine but not with famotidine. | 2006 May |
|
Gastroprotective and antioxidant effects of montelukast on indomethacin-induced gastric ulcer in rats. | 2007 Sep |
|
Severe hypomagnesaemia due to lansoprazole. | 2009 |
|
Drug-induced aseptic meningitis, sensorineural hearing loss and vestibulopaty. | 2010 Sep |
|
Attenuation of stress-induced gastric lesions by lansoprazole, PD-136450 and ranitidine in rats. | 2011 Mar |
|
Discovery of two clinical histamine H(3) receptor antagonists: trans-N-ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidinylmethyl)phenyl]cyclobutanecarboxamide (PF-03654746) and trans-3-fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]-N-(2-methylpropyl)cyclobutanecarboxamide (PF-03654764). | 2011 Nov 10 |
|
The mediation of the central histaminergic system in the pressor effect of intracerebroventricularly injected melittin, a phospholipase A2 activator, in normotensive rats. | 2012 Oct-Nov |
|
Gastroprotective effects of goniothalamin against ethanol and indomethacin-induced gastric lesions in rats: Role of prostaglandins, nitric oxide and sulfhydryl compounds. | 2014 Dec 5 |
|
A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans. | 2014 Jan |
Patents
Sample Use Guides
In Vivo Use Guide
Curator's Comment: In some hospitalized patients with pathological hypersecretory conditions or intractable duodenal ulcers, or in patients unable to take oral medication, ZANTAC® may be administered parenterally (intramuscular or intravenous injections): 50 mg (2 mL) every six to eight hours.
150 mg twice daily (tablets or syrup)
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25725698
10uM ranitidine partially suppresses histamine-elicited signaling in human tubular epithelial cells
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 19:38:28 UTC 2022
by
admin
on
Fri Dec 16 19:38:28 UTC 2022
|
Record UNII |
884KT10YB7
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
A02BA02
Created by
admin on Fri Dec 16 19:38:29 UTC 2022 , Edited by admin on Fri Dec 16 19:38:29 UTC 2022
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
17.1
Created by
admin on Fri Dec 16 19:38:29 UTC 2022 , Edited by admin on Fri Dec 16 19:38:29 UTC 2022
|
||
|
NDF-RT |
N0000175784
Created by
admin on Fri Dec 16 19:38:29 UTC 2022 , Edited by admin on Fri Dec 16 19:38:29 UTC 2022
|
||
|
WHO-ATC |
A02BA07
Created by
admin on Fri Dec 16 19:38:29 UTC 2022 , Edited by admin on Fri Dec 16 19:38:29 UTC 2022
|
||
|
NDF-RT |
N0000000151
Created by
admin on Fri Dec 16 19:38:29 UTC 2022 , Edited by admin on Fri Dec 16 19:38:29 UTC 2022
|
||
|
LIVERTOX |
NBK548867
Created by
admin on Fri Dec 16 19:38:29 UTC 2022 , Edited by admin on Fri Dec 16 19:38:29 UTC 2022
|
||
|
WHO-VATC |
QA02BA02
Created by
admin on Fri Dec 16 19:38:29 UTC 2022 , Edited by admin on Fri Dec 16 19:38:29 UTC 2022
|
||
|
NCI_THESAURUS |
C29702
Created by
admin on Fri Dec 16 19:38:29 UTC 2022 , Edited by admin on Fri Dec 16 19:38:29 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
9143
Created by
admin on Fri Dec 16 19:38:29 UTC 2022 , Edited by admin on Fri Dec 16 19:38:29 UTC 2022
|
PRIMARY | RxNorm | ||
|
1234
Created by
admin on Fri Dec 16 19:38:29 UTC 2022 , Edited by admin on Fri Dec 16 19:38:29 UTC 2022
|
PRIMARY | |||
|
8776
Created by
admin on Fri Dec 16 19:38:29 UTC 2022 , Edited by admin on Fri Dec 16 19:38:29 UTC 2022
|
PRIMARY | |||
|
SUB10258MIG
Created by
admin on Fri Dec 16 19:38:29 UTC 2022 , Edited by admin on Fri Dec 16 19:38:29 UTC 2022
|
PRIMARY | |||
|
884KT10YB7
Created by
admin on Fri Dec 16 19:38:29 UTC 2022 , Edited by admin on Fri Dec 16 19:38:29 UTC 2022
|
PRIMARY | |||
|
RANITIDINE
Created by
admin on Fri Dec 16 19:38:29 UTC 2022 , Edited by admin on Fri Dec 16 19:38:29 UTC 2022
|
PRIMARY | |||
|
657345
Created by
admin on Fri Dec 16 19:38:29 UTC 2022 , Edited by admin on Fri Dec 16 19:38:29 UTC 2022
|
PRIMARY | |||
|
CHEMBL1790041
Created by
admin on Fri Dec 16 19:38:29 UTC 2022 , Edited by admin on Fri Dec 16 19:38:29 UTC 2022
|
PRIMARY | |||
|
DTXSID8045191
Created by
admin on Fri Dec 16 19:38:29 UTC 2022 , Edited by admin on Fri Dec 16 19:38:29 UTC 2022
|
PRIMARY | |||
|
Ranitidine
Created by
admin on Fri Dec 16 19:38:29 UTC 2022 , Edited by admin on Fri Dec 16 19:38:29 UTC 2022
|
PRIMARY | |||
|
757851
Created by
admin on Fri Dec 16 19:38:29 UTC 2022 , Edited by admin on Fri Dec 16 19:38:29 UTC 2022
|
PRIMARY | |||
|
2358
Created by
admin on Fri Dec 16 19:38:29 UTC 2022 , Edited by admin on Fri Dec 16 19:38:29 UTC 2022
|
PRIMARY | |||
|
DB00863
Created by
admin on Fri Dec 16 19:38:29 UTC 2022 , Edited by admin on Fri Dec 16 19:38:29 UTC 2022
|
PRIMARY | |||
|
66357-35-5
Created by
admin on Fri Dec 16 19:38:29 UTC 2022 , Edited by admin on Fri Dec 16 19:38:29 UTC 2022
|
PRIMARY | |||
|
D011899
Created by
admin on Fri Dec 16 19:38:29 UTC 2022 , Edited by admin on Fri Dec 16 19:38:29 UTC 2022
|
PRIMARY | |||
|
884KT10YB7
Created by
admin on Fri Dec 16 19:38:29 UTC 2022 , Edited by admin on Fri Dec 16 19:38:29 UTC 2022
|
PRIMARY | |||
|
266-332-5
Created by
admin on Fri Dec 16 19:38:29 UTC 2022 , Edited by admin on Fri Dec 16 19:38:29 UTC 2022
|
PRIMARY | |||
|
M9498
Created by
admin on Fri Dec 16 19:38:29 UTC 2022 , Edited by admin on Fri Dec 16 19:38:29 UTC 2022
|
PRIMARY | Merck Index | ||
|
3925
Created by
admin on Fri Dec 16 19:38:29 UTC 2022 , Edited by admin on Fri Dec 16 19:38:29 UTC 2022
|
PRIMARY | |||
|
C29412
Created by
admin on Fri Dec 16 19:38:29 UTC 2022 , Edited by admin on Fri Dec 16 19:38:29 UTC 2022
|
PRIMARY | |||
|
4660
Created by
admin on Fri Dec 16 19:38:29 UTC 2022 , Edited by admin on Fri Dec 16 19:38:29 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> SUBSTRATE | |||
|
TRANSPORTER -> SUBSTRATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE INACTIVE -> PARENT |
MINOR
|
||
|
METABOLITE INACTIVE -> PARENT | |||
|
METABOLITE INACTIVE -> PARENT | |||
|
METABOLITE INACTIVE -> PARENT |
MINOR
URINE
|
||
|
METABOLITE INACTIVE -> PARENT |
MINOR
URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Route of Elimination | PHARMACOKINETIC |
|
|
|||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
ELDERLY: 3 - 4 HOURS |
|
||
MAXIMUM TOLERATED DOSE | TOXICITY |
|
NON-ULCER INDIGESTION, PROPHYLAXIS AND TREATMENT: 300 MG/DAY |
|
||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
PROTEIN BINDING | PHARMACOKINETIC |
|
|
|||